UK Screening Committee’s Prostate Cancer Screening Recommendations

The National Screening Committee in the UK has suggested that only a narrow segment of men at a high risk of prostate cancer should undergo screening for the disease.

Presently, there is no specific screening program for prostate cancer, which is the most prevalent cancer among men.

There has been vigorous advocacy for change from various high-profile individuals, including Sir Chris Hoy, who has terminal prostate cancer, and former Prime Minister Lord David Cameron, who recently disclosed his treatment for the disease.

This expert advice will be under consultation for the next three months, after which the committee will relay its final recommendations to the governments of the four UK nations by March.

What is Screening?

Screening refers to the process of inviting individuals for tests aimed at detecting diseases even when they show no symptoms.

For instance, women may be asked to undergo mammograms for breast cancer, while a home test for bowel cancer is sent to individuals over 50 every two years.

The purpose is to identify cancers early—ideally before symptoms arise—when treatment remains possible.

What Was Recommended Today?

Experts determined that there is no justification for broadly screening the majority of men for prostate cancer.

After reviewing available evidence, they concluded screening is only appropriate for:

• men who have a genetic predisposition to prostate cancer (specifically, those with a confirmed BRCA gene variant).

This specific group is advised to undergo screening every two years between the ages of 45 and 61.

This means, notably, that other high-risk groups, including:

• black men
• men with a family history of prostate cancer

are not recommended for screening.

Why Did They Reach This Conclusion?

The UK National Screening Committee concluded that implementing a widespread screening program for prostate cancer could potentially do more harm than good.

The tests available are not entirely reliable and could lead men to receive treatments for slow-growing cancers that may never harm them. Such treatments can result in side effects like incontinence and impotence, significantly impacting quality of life.

While catching cancers early is important and can save lives, determining which cancers are aggressive poses challenges for doctors. Consequently, many men might endure unnecessary treatments.

The committee asserted that the number of lives potentially saved through screening does not justify its adverse effects on healthy individuals.

Why Not Screen All High-Risk Men?

Many had anticipated that all men at high risk would be included in new screening recommendations.

Nonetheless, the committee did not endorse that broader approach.

Even though black men face double the risk for prostate cancer, the committee noted the lack of clarity regarding the screening’s impacts and pointed out insufficient evidence from clinical trials in this demographic.

Similarly, they advised against screening men with familial histories of the disease, citing concerns over overdiagnosis and overtreatment.

However, men with specific genetic mutations—the BRCA variants—are more prone to developing aggressive cancers at a younger age, thus justifying screening for them.

Treating these cancers earlier can offer more substantial benefits compared to risks associated with unnecessary interventions for the general population, the experts conveyed.

How Do You Test for BRCA Variants?

A genetic test is required to detect mutations in the BRCA 1 and 2 genes.

These variants affect both men and women, raising the risk of various cancers, including prostate, breast, and ovarian cancers.

It’s estimated that around three in every 1,000 men have these BRCA mutations, but many may not be aware unless their family history indicates it and they have confirmed it through testing.

Experts believe that more genetic testing will need to be offered to high-risk men moving forward to assess the number affected.

How Many Men Get Prostate Cancer?

Prostate cancer remains the most common cancer among men.

Each year, approximately 55,000 men receive a diagnosis, and about 12,000 succumb to the disease in the UK.

Is This the Final Word on Screening?

No, a three-month consultation concerning these recommendations begins now.

The committee will reconvene afterward to give final advice to ministers in England, Wales, Northern Ireland, and Scotland.

They will then have to independently decide on prostate screening initiatives.

Wes Streeting, the Health Secretary in England, has expressed a desire for screening but insists it must be “backed by evidence.”

He stated he would thoroughly examine the evidence prior to reaching a final decision in March.